 |
|
|
| |
GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED
REGIMEN FROM NNRTI VS. PI REGIMENS
|
| |
| |
CROI 2020 March 10
Reported by Jules Levin
John Koethe1, Aihua Bian1, Peter F. Rebeiro1, Cathy Jenkins1, Kassem Bourgi2, Richard D. Moore3, Michael Saag4, Kathryn Anastos5, Julia Fleming6, Marina Klein7, Viviane D. Lima8, Joseph B. Margolick3, Timothy R. Sterling1, Jordan E. Lake9, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
1Vanderbilt University, Nashville, TN, USA, 2Indiana University, Indianapolis, IN, USA, 3Johns Hopkins University, Baltimore, MD, USA, 4University of Alabama at Birmingham, Birmingham, AL, USA, 5Montefiore Medical Center, Bronx, NY, USA, 6Fenway Health, Boston, MA, USA, 7McGill University, Montreal, QC, Canada, 8British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, 9University of Texas at Houston, Houston, TX, USA
References:
1. Koethe JR et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Research and Human Retroviruses 2016; 32(1): 50-8.
2. Nansseu JR et al. Incidence and risk factors for prediabetes and diabetes mellitus among HIV infected adults on antiretroviral therapy: systematic review and meta-analysis. Epidemiology 2018;29(3):431-441.
3. Worm SW et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009;32(3):474-80
4. Bourgi K et al. Greater weight gain in treatment naïve persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019 [Epub ahead of print].
5. Sax PE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019 [Epub ahead of print].
|
| |
|
|
|
|
|
